Daneshvar Kakhaki, R. and Ostadmohammadi, V. and Kouchaki, E. and Aghadavod, E. and Bahmani, F. and Tamtaji, O.R. and J.Reiter, R. and Mansournia, M.A. and Asemi, Z. (2020) Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clinical Neurology and Neurosurgery, 195.
Full text not available from this repository.Abstract
Objective: This study was performed to evaluate the impact of melatonin supplementation on clinical and metabolic profiles in people with Parkinson's disease (PD). Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted among 60 patients with PD. Participants were randomly divided into two groups to intake either 10 mg melatonin (two melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day, 1 h before bedtime for 12 weeks. Results: Melatonin supplementation significantly reduced the Unified Parkinson's Disease Rating Scale (UPDRS) part I score (β �2.33; 95 CI, �3.57, �1.09; P < 0.001), Pittsburgh Sleep Quality Index (PSQI) (β �1.82; 95 CI, �3.36, �0.27; P = 0.02), Beck Depression Inventory (BDI) (β �3.32; 95 CI, �5.23, �1.41; P = 0.001) and Beck Anxiety Inventory (BAI) (β �2.22; 95 CI, �3.84, �0.60; P = 0.008) compared with the placebo treatment. Compared with the placebo, melatonin supplementation resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β �0.94 mg/L; 95 CI, �1.55, �0.32; P = 0.003) and a significant elevation in plasma total antioxidant capacity (TAC) (β 108.09 mmol/L; 95 CI, 78.21, 137.97; P < 0.001) and total glutathione (GSH) levels (β 77.08 μmol/L; 95 CI, 44.29, 109.86; P < 0.001). Additionally, consuming melatonin significantly decreased serum insulin levels (β �1.79 μIU/mL; 95 CI, �3.12, �0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β �0.47; 95 CI, �0.80, �0.13; P = 0.007), total- (β �13.16 mg/dL; 95 CI, �25.14, �1.17; P = 0.03) and LDL- (β �10.44 mg/dL; 95 CI, �20.55, �0.34; P = 0.04) compared with the placebo. Conclusions: Overall, melatonin supplementation for 12 weeks to patients with PD had favorable effects on the UPDRS part I score, PSQI, BDI, BAI, hs-CRP, TAC, GSH, insulin levels, HOMA-IR, total-, LDL-cholesterol, and gene expression of TNF-α, PPAR-γ and LDLR, but did not affect other metabolic profiles. © 2020 Elsevier B.V.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 0 |
| Uncontrolled Keywords: | C reactive protein; glutathione; melatonin; placebo, adult; aged; antioxidant activity; Article; Beck Anxiety Inventory; Beck Depression Inventory; bedtime dosage; controlled study; double blind procedure; evaluation study; female; homeostasis model assessment; human; insulin blood level; major clinical study; male; metabolism; Parkinson disease; Pittsburgh Sleep Quality Index; protein blood level; randomized controlled trial; supplementation; treatment duration; Unified Parkinson Disease Rating Scale |
| Subjects: | Nutrition Endocrinology Metabolism Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics |
| Divisions: | Faculty of Medicine > Basic Sciences > Department of Biochemistry |
| Depositing User: | ART . editor |
| Date Deposited: | 28 Jun 2020 09:58 |
| Last Modified: | 28 Jun 2020 09:58 |
| URI: | http://eprints.kaums.ac.ir/id/eprint/4877 |
Actions (login required)
 |
View Item |
